Study summary
An injected cancer-killing virus shrank tumors after immunotherapy failed
32.9%of tumors shrank
What was tested
RP1 (vusolimogene oderparepvec), a modified herpes virus injected into tumors, plus nivolumab, for advanced melanoma that grew on anti-PD-1 therapy.
What they found
- Tumors shrank in 32.9%, with 15% complete responses.
- Responses appeared in uninjected tumors too, including in organs.
What it means
One of few options after immunotherapy stops working; regulators asked for more evidence before approval.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.